kpv vs bpc-157
updated
kpv (tier B) vs bpc-157 (tier A): what each is, why each got its grade, half-life and source counts side by side.
kpv · tier B
tiny three-amino-acid peptide for inflammation. IBD, eczema, autoimmune. none of α-MSH's tanning or appetite side effects.
tier rationale
B-tier because the preclinical evidence is substantial and the mechanism is well-characterized, but human clinical trials are limited and U.S. compounding status is unsettled. KPV appears in combination blends like KLOW and has a coherent mucosal anti-inflammatory thesis, but it does not have phase 3 evidence or a formal approval pathway. Pharmacologically elegant, clinically underbuilt.
bpc-157 · tier A
the contested repair peptide. strong animal data, thin human trials, huge community gravity.
tier rationale
A-tier because the preclinical evidence is extraordinary and the community signal is persistent. Not S-tier because drug-grade human evidence does not exist, long-term human safety is not characterized, and the single-lab concentration matters. If independent controlled trials ever hold up, the tier can move. Until then, A is the ceiling.
at a glance
| kpv | bpc-157 | |
|---|---|---|
| tier | B | A |
| category | healing / tissue | healing / tissue |
| sources | 25 | 37 |
| claims evaluated | 6 | 9 |
| half-life | short in plasma; stable in GI tract | short |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.